SH PHARMA (601607.SH) announced that its subsidiary, Shandong Xinyi Pharmaceutical Co., Ltd., recently received a "Drug Supplement Application Approval Notice" (Notice No.: 2026B02904) from the National Medical Products Administration. The notice approves the transfer of the marketing authorization for Trazodone Hydrochloride Tablets to Shandong Xinyi Pharmaceutical Co., Ltd.

Trazodone Hydrochloride Tablets, a product originally approved for marketing in China in 2025 by Hebei Longhai Pharmaceutical Co., Ltd., are indicated for the treatment of depression and are effective for patients with or without accompanying anxiety. In May 2026, Shandong Xinyi submitted a registration application to the NMPA for the change in marketing authorization holder for this drug, which has now been approved.

As of the announcement date, the company has invested approximately RMB 5.2 million in this product.